DFDA

Intranasal Corticosteroids (INCS)

Treatment for Allergic Rhinitis

Typical Dosage: 1-2 sprays per nostril once daily (e.g., Fluticasone propionate 50 mcg/spray)

Effectiveness
88%
Safety Score
78%
Clinical Trials
6
Participants
300K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
1-2 sprays per nostril once daily (e.g., Fluticasone propionate 50 mcg/spray)
Time to Effect
Several days to 2 weeks for maximal effect
Treatment Duration
Seasonal or perennial (long-term)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$50
Side Effect Mgmt:$15
Total Annual:$215
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$286.67
Cost per Remission
$430
Intranasal Corticosteroids (INCS) Outcomes

for Allergic Rhinitis

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+50%
Common Side Effects
Nasal irritation/dryness
+15%
Epistaxis (nosebleed)
+10%
Sore throat
+7%
Headache
+8%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Intranasal Corticosteroids (INCS) in Allergic Rhinitis

A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms

NCT07294326NOT YET RECRUITINGPHASE4
View Study
50 participants
INTERVENTIONAL
Started: Jan 1, 2026

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008RECRUITINGPHASE3
View Study
450 participants
INTERVENTIONAL
Huntington Beach, United States +71 more
Started: Apr 26, 2024
Completed Clinical Trials
4 completed trials for Intranasal Corticosteroids (INCS) in Allergic Rhinitis

Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge

NCT01657097COMPLETEDPHASE4
View Study
24 participants
INTERVENTIONAL
Aarhus, Denmark
Started: Feb 1, 1997

Evaluation of the Animated Cartoon-aided Teaching of Intranasal Corticosteroid Allergic Rhinitis

NCT02571413COMPLETEDNA
View Study
80 participants
INTERVENTIONAL
Bangkok, Thailand
Started: May 1, 2009

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

NCT05299086COMPLETEDPHASE3
View Study
68 participants
INTERVENTIONAL
Bangkok, Thailand
Started: Apr 4, 2022

Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis

NCT07016763COMPLETEDEARLY_PHASE1
View Study
400 participants
INTERVENTIONAL
Rome, Italy
Started: Sep 1, 2024